Search Results

The Elecsys IGRA TB test delivers results in under 24 hours and brings automated latent tuberculosis screening to Roche's cobas immunoassay platforms. Roche has received CE Mark approval for its Elecsys Interferon Gamma Release Assay (IGRA) TB test, a blood-based diagnostic designed to detect latent tuberculosis infection (TBI) in routine laboratory settings. The automated assay is designed to improve testing efficiency by running on Roche's cobas immunoassay systems, helping laboratories increase throughput while reducing manual workflows. Faster, Automated TB Screening The Elecsys IGRA TB test delivers results in less than 24 hours, with each assay requiring approximately 19 minutes to process. By integrating automated sample handling and digital workflows, the system is intended to support growing demand for latent tuberculosis screening while improving laboratory efficiency. Roche says the platform offers faster turnaround times and greater testing capacity compared with traditional manual testing methods. Supporting Global Tuberculosis Control Latent tuberculosis occurs when individuals are infected with Mycobacterium tuberculosis but do not show symptoms of active disease. Without diagnosis and treatment, latent infection can later progress to active tuberculosis, contributing to ongoing disease transmission and mortality. The World Health Organization (WHO) has identified improved diagnosis and treatment of latent TB as a key component of its strategy to reduce tuberculosis deaths by 90% and new cases by 80% by 2030. Roche believes wider access to automated diagnostics could help support these global elimination efforts. Clinical Study Demonstrates Strong Performance The CE Mark approval was supported by a global multi-centre clinical evaluation conducted across regions with both high and low tuberculosis incidence, including Europe, Africa, the Western Pacific and the Americas. Compared with existing standard testing methods, the Elecsys IGRA TB assay demonstrated: 91.12% positive percent agreement 94.57% negative percent agreement 100% relative sensitivity in patients with bacteriologically confirmed tuberculosis 95.32% specificity in a low-risk patient cohort The findings indicate the assay can accurately identify latent tuberculosis infection while maintaining strong diagnostic performance across diverse populations. Expanding Roche's Diagnostics Portfolio The approval further strengthens Roche's diagnostics business as the company continues to invest in laboratory automation and molecular testing technologies. It follows the recent launch of Axelios 1, Roche's next-generation sequencing platform for research applications, reflecting the company's continued focus on expanding its diagnostic capabilities. Why the CE Mark Matters The approval highlights several important trends across diagnostic medicine: Automated laboratory testing is helping improve efficiency and scalability for infectious disease screening. Early identification of latent tuberculosis remains central to global disease elimination strategies. Blood-based diagnostics are increasingly replacing more labour-intensive testing workflows. Integrated laboratory platforms continue to play a growing role in public health screening programmes. Summary Roche has secured CE Mark approval for its Elecsys IGRA TB blood test, providing laboratories with an automated solution for detecting latent tuberculosis infection. Designed for use on Roche's cobas immunoassay systems, the assay delivers rapid, high-throughput testing and supports global efforts to improve tuberculosis screening and reduce the burden of one of the world's leading infectious diseases. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The DE STSF platform combines radiofrequency and pulsed field ablation in a single catheter, expanding treatment options for electrophysiologists managing complex cardiac arrhythmias. Johnson & Johnson has received US Food and Drug Administration (FDA) approval for its Dual Energy Thermocool Smarttouch SF (DE STSF) platform, a catheter ablation system that enables physicians to deliver both radiofrequency (RF) and pulsed field (PF) energy using a single device. The approval expands the company's electrophysiology portfolio by giving clinicians greater flexibility to tailor ablation strategies based on individual patient anatomy and procedural requirements. Dual-Energy Approach to Catheter Ablation The DE STSF platform builds on Johnson & Johnson's established Thermocool Smarttouch SF technology, which the company says has been used to treat more than one million patients in the United States. The addition of pulsed field ablation allows physicians to choose between two different energy sources during procedures: Radiofrequency (RF) ablation, which uses heat to destroy abnormal cardiac tissue. Pulsed field (PF) ablation, a newer, non-thermal technology that selectively targets cardiac cells using electrical pulses. Providing both options through a single catheter is intended to simplify workflows while allowing clinicians to adapt treatment to different clinical scenarios. Integrated with the CARTO Platform The DE STSF system is fully integrated with Johnson & Johnson's CARTO mapping ecosystem. The platform combines advanced cardiac mapping, imaging capabilities and PF Index guidance to help physicians visualise anatomy and accurately deliver ablation therapy. According to the company, the integrated system is designed to support precise catheter contact, predictable energy delivery and more consistent procedural workflows. Commercial Rollout Planned for Later This Year Following FDA approval, Johnson & Johnson expects the first US procedures using the DE STSF platform to take place later this year as part of a phased commercial launch. The approval follows the technology's earlier introduction in Europe, where the platform has already entered clinical use. Company executives said the launch represents another milestone during a period of significant innovation within the electrophysiology market. Growing Innovation in Cardiac Electrophysiology Demand for advanced catheter ablation technologies continues to increase as physicians seek safer, more effective treatments for cardiac arrhythmias such as atrial fibrillation. Pulsed field ablation has emerged as one of the fastest-growing technologies in electrophysiology due to its potential to reduce damage to surrounding tissue while maintaining procedural effectiveness. Johnson & Johnson continues to expand its cardiovascular device portfolio, having recently initiated enrolment in its SKYWARD investigational device exemption study evaluating the Shockwave SkyRunner Carotid intravascular lithotripsy system. Why the Approval Matters The FDA approval reflects several key trends across cardiovascular medical technology: Dual-energy ablation systems are providing physicians with greater procedural flexibility. Pulsed field ablation continues to gain momentum as a next-generation treatment approach. Integration of mapping, imaging and navigation technologies is improving procedural precision. Competition within the electrophysiology market is accelerating as manufacturers expand their cardiac device portfolios. Summary Johnson & Johnson has secured FDA approval for its Dual Energy Thermocool Smarttouch SF platform, enabling physicians to perform both radiofrequency and pulsed field catheter ablation using a single system. Integrated with the CARTO ecosystem, the platform offers greater flexibility for treating complex cardiac arrhythmias and further strengthens Johnson & Johnson's position in the rapidly evolving electrophysiology market. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The new funding will accelerate manufacturing and commercial deployment of the FDA-cleared Marie system, which reimagines proton therapy by rotating the patient instead of the treatment machine. Leo Cancer Care has secured $65 million in Series D financing to expand manufacturing and commercial deployment of its Marie upright radiotherapy platform, following growing interest in the company's patient-centred approach to cancer treatment. The oversubscribed funding round was led by Yu Galaxy and included participation from new investor Eventide Asset Management, alongside existing shareholders. Funding to Accelerate Commercial Growth The latest investment follows Leo Cancer Care's $40 million fundraising completed in September 2025. According to the company, the new capital will be used to: Expand manufacturing capacity. Accelerate commercial deployment of the Marie platform. Support ongoing clinical research and product development. Advance its broader upright radiotherapy strategy across proton therapy, photon therapy and medical imaging. Rethinking Radiotherapy Delivery At the centre of Leo's technology is Marie, an integrated upright patient positioning system and CT scanner designed for proton therapy. Unlike conventional radiotherapy systems, where a large gantry rotates around a patient lying flat, Marie keeps the treatment equipment fixed while rotating the patient into the required treatment position. The company believes this upright approach can improve anatomical consistency and organ stability during treatment, potentially enhancing treatment precision while simplifying system design. Building Momentum Following FDA Clearance Marie received US Food and Drug Administration (FDA) 510(k) clearance in July 2025. Since then, the platform has attracted growing interest from leading cancer centres. In June, the system was used during the world's first compact upright proton therapy treatment at Stanford Medicine Cancer Center, demonstrating the clinical feasibility of the company's novel treatment approach. The milestone marked an important step towards broader adoption of upright proton therapy in clinical practice. Expanding Access to Advanced Cancer Care Leo Cancer Care says its long-term strategy is to redesign radiotherapy around the patient rather than the treatment machine. The company believes upright treatment systems could make advanced cancer therapies more accessible by reducing infrastructure requirements while maintaining treatment quality. Alongside the financing announcement, Leo also revealed it is preparing to announce a strategic partnership with a major international healthcare company, with further details expected in the coming weeks. Why the Funding Matters The investment reflects several important trends across radiation oncology: Companies are exploring new treatment workflows that improve both patient experience and operational efficiency. Proton therapy continues to expand beyond specialist centres through more compact technologies. Innovation is increasingly focused on improving access to advanced radiotherapy rather than simply reducing equipment costs. Investors remain supportive of technologies that could reshape cancer treatment delivery. Summary Leo Cancer Care has raised $65 million to accelerate commercial rollout of its FDA-cleared Marie upright radiotherapy platform. The funding will support manufacturing expansion, clinical development and broader deployment of a system designed to transform proton therapy by rotating the patient rather than the treatment machine, as interest in upright cancer treatment continues to grow. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The anti-CD122 monoclonal antibody demonstrated significant improvements in facial vitiligo scores, with results supporting further clinical development in autoimmune dermatology. Forte Biosciences has reported positive Phase Ib clinical data for FB102, an investigational anti-CD122 monoclonal antibody being developed as a potential treatment for vitiligo. The company said the therapy demonstrated significant improvements in facial vitiligo severity compared with placebo, while maintaining a favourable safety profile. Following the data announcement, shares in Forte Biosciences rose more than 55%, reflecting investor optimism around FB102’s potential to become a new treatment option for patients with autoimmune skin disease. How FB102 Works FB102 is designed to block CD122, a receptor involved in signalling pathways associated with interleukin-2 (IL-2) and interleukin-15 (IL-15). These immune pathways play an important role in regulating pathogenic T-cell activity linked to autoimmune diseases. Unlike approaches that exclusively target IL-15 signalling, Forte believes selective CD122 modulation may provide broader immune pathway control while preserving regulatory T-cell activity. Phase Ib Trial Shows Improvement in Vitiligo Symptoms In the Phase Ib study, FB102 demonstrated improvements across multiple measures of facial vitiligo severity. In the intent-to-treat population, patients receiving FB102 achieved a 29.6% mean improvement in Facial Vitiligo Area Scoring Index (FVASI) from baseline to week 24. This compared with a 16.2% worsening among placebo patients, representing a placebo-adjusted benefit of 45.8% in favour of FB102. Among patients with more extensive facial disease, FB102 produced a 43.2% mean improvement at week 24 compared with 0.5% for placebo. Nearly 59% of these patients achieved FVASI50, representing at least a 50% improvement in facial vitiligo, while 23.5% achieved FVASI75. Treatment Effects Continued After Dosing Ended Forte reported that FB102 demonstrated an early onset of activity, with statistically significant improvements observed by day 64. Importantly, improvements continued after treatment ended, with an additional eight percentage point improvement in FVASI scores between weeks 12 and 24 despite dosing stopping after 12 weeks. The company said FB102 was generally well tolerated, with adverse events described as mild-to-moderate and a safety profile comparable with placebo. Vitiligo Treatment Landscape Vitiligo is a chronic autoimmune condition where immune-mediated destruction of melanocytes causes loss of skin pigmentation. The disease affects millions of people worldwide and can significantly impact quality of life. Currently, Incyte’s Opzelura (ruxolitinib) cream remains the only FDA-approved therapy specifically indicated for repigmentation in non-segmental vitiligo. Competition in the space is increasing, with Incyte also advancing oral povorcitinib, a JAK1 inhibitor that recently achieved positive Phase III results in vitiligo trials. Next Steps for FB102 Forte Biosciences is continuing development of FB102 across autoimmune diseases. The company is also evaluating the therapy in coeliac disease, where Phase II data could provide another important clinical milestone. Positive results in vitiligo could position FB102 as a differentiated immunology approach targeting underlying disease biology rather than only treating symptoms. Why This Matters The latest results add to growing interest in immune-modulating therapies for dermatology and autoimmune disease. While existing treatments such as JAK inhibitors have demonstrated clinical benefit, new approaches targeting specific immune pathways could expand treatment options for patients with moderate-to-severe vitiligo. FB102 now moves forward as one of several emerging therapies aiming to reshape the future of autoimmune dermatology. Summary Forte Biosciences has reported positive Phase Ib results for FB102, an investigational anti-CD122 monoclonal antibody being developed as a potential treatment for vitiligo. The therapy demonstrated significant improvements in facial vitiligo scores compared with placebo, with continued benefit observed after dosing ended and a favourable safety profile. The results position FB102 as an emerging candidate in the growing vitiligo treatment landscape, where pharmaceutical companies are increasingly developing targeted immune therapies to improve repigmentation and address the underlying autoimmune drivers of the disease. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

New formulation expands Sanofi’s Sarclisa portfolio by offering a subcutaneous delivery option across multiple myeloma treatment settings, including newly diagnosed, relapsed and refractory disease. The US Food and Drug Administration (FDA) has approved a subcutaneous formulation of isatuximab-irfc (Sarclisa Escena) for the treatment of adults with multiple myeloma across three approved treatment combinations. The approval provides patients and healthcare professionals with an alternative administration method to the existing intravenous formulation of the Sanofi-developed anti-CD38 monoclonal antibody. The FDA decision was supported by clinical data demonstrating that subcutaneous isatuximab-irfc delivered comparable efficacy to intravenous administration, while offering the potential for a more convenient treatment experience through reduced administration burden. Subcutaneous Sarclisa Matches Intravenous Efficacy in Phase III Study The primary evidence supporting the FDA approval came from the Phase III IRAKLIA trial (NCT05405166), which evaluated whether subcutaneous administration could provide similar outcomes to the existing intravenous formulation. The open-label, randomised non-inferiority study enrolled 531 patients with multiple myeloma, assigning participants to receive either subcutaneous isatuximab-irfc with an on-body delivery system or intravenous isatuximab-irfc, both alongside pomalidomide and dexamethasone. The study met its key objectives: Overall response rate (ORR) was 71.1% in the subcutaneous treatment group compared with 70.5% in the intravenous group. Drug exposure levels were comparable, with steady-state trough concentrations favouring subcutaneous administration. The results demonstrated that subcutaneous Sarclisa maintained the clinical activity of intravenous therapy while providing an alternative delivery option for patients. Additional Clinical Data Support Broader Multiple Myeloma Use The FDA approval was also supported by data from additional clinical studies evaluating subcutaneous isatuximab-irfc in different multiple myeloma populations. In the Phase II IZALCO study (NCT05704049), subcutaneous Sarclisa was evaluated in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. The study reported: Overall response rate of 79.7% based on independent review committee assessment. The Phase II IsaSocut study (NCT05889221) evaluated subcutaneous isatuximab-irfc alongside bortezomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients who were not eligible for stem cell transplantation. The study demonstrated: Overall response rate of 97.3%. Together, these results supported the use of subcutaneous Sarclisa across multiple stages of multiple myeloma treatment. Addressing Treatment Burden in Multiple Myeloma Care Multiple myeloma remains a complex blood cancer requiring long-term treatment approaches involving combinations of targeted therapies, immunomodulatory drugs and corticosteroids. While anti-CD38 antibodies such as isatuximab-irfc have become important components of multiple myeloma treatment, intravenous administration can increase clinic time and place additional demands on healthcare systems. The introduction of a subcutaneous formulation could help simplify treatment delivery by providing a potentially faster and more flexible administration approach. The move also reflects a wider trend across oncology, where pharmaceutical companies are increasingly developing subcutaneous versions of established biologic therapies to improve patient convenience and optimise healthcare resource use. Sarclisa Safety Profile Remains Consistent The FDA prescribing information includes warnings and precautions relating to: Hypersensitivity and administration-related reactions Neutropenia Infections Secondary primary malignancies Laboratory test interference Embryo-fetal toxicity Healthcare professionals are advised to monitor patients for potential adverse reactions during treatment. What the FDA Approval Means for Multiple Myeloma Treatment The approval of subcutaneous Sarclisa expands treatment options for patients with multiple myeloma by providing an alternative to intravenous administration without compromising clinical efficacy. With positive results from the Phase III IRAKLIA study and supporting Phase II data across multiple treatment settings, Sanofi’s Sarclisa portfolio is positioned to play a broader role in the evolving multiple myeloma treatment landscape. As oncology care continues to move towards more convenient and patient-centred delivery models, subcutaneous biologics are expected to become an increasingly important part of long-term cancer management. Summary The FDA has approved subcutaneous isatuximab-irfc (Sarclisa Escena) for adults with multiple myeloma across newly diagnosed, relapsed and refractory treatment settings. The approval was supported by the Phase III IRAKLIA trial, which showed comparable efficacy between subcutaneous and intravenous administration, alongside additional Phase II studies demonstrating strong response rates in different patient populations. The new formulation expands Sanofi’s multiple myeloma offering while supporting a broader shift towards more convenient cancer treatment delivery. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The ALARION-EV trial will evaluate AtaCor Medical’s investigational parasternal extravascular implantable cardioverter-defibrillator (EV-ICD) system, designed to provide an alternative approach to traditional ICD therapy for patients at risk of life-threatening arrhythmias. AtaCor Medical has enrolled the first patient in its pivotal ALARION-EV clinical trial evaluating its investigational extravascular implantable cardioverter-defibrillator (EV-ICD) system, marking a key milestone in the development of next-generation cardiac rhythm management technology. The multicentre study will assess the safety and effectiveness of AtaCor’s EV-ICD system in patients who require defibrillation therapy but do not need chronic pacing support for slow heart rhythms. The trial represents an important step towards expanding ICD treatment options by evaluating a system designed to avoid placement of leads inside the heart and blood vessels. What Is AtaCor’s Extravascular ICD System? Traditional implantable cardioverter-defibrillators (ICDs) use leads positioned inside the heart to detect abnormal rhythms and deliver electrical shocks when required. AtaCor’s EV-ICD approach uses an extravascular design, meaning the system is implanted outside the heart and vascular system. The investigational system combines: AtaCor’s Atala lead, implanted through a small left parasternal incision with electrodes positioned against the pericardium. Abbott’s pulse generator, positioned in either a lateral or pectoral device pocket. The company believes this approach could provide an alternative option for patients requiring defibrillation therapy while reducing some limitations associated with traditional transvenous ICD systems. ALARION-EV Pivotal Trial Design The prospective, multicentre, single-arm ALARION-EV study will enrol approximately 280 patients across up to 40 clinical sites in the United States and the Netherlands. The trial is designed for patients who require ICD therapy but do not require chronic pacing for bradycardia. Researchers will evaluate the safety and effectiveness of the investigational parasternal EV-ICD system through at least six months of follow-up. Data generated from the study are expected to support a future Premarket Approval (PMA) submission to the US Food and Drug Administration (FDA). Advancing Next-Generation Cardiac Rhythm Management AtaCor Medical said the first patient treatment represents a significant milestone in its efforts to develop new approaches to cardiac rhythm management. Rick Sanghera, CEO of AtaCor Medical, said the achievement reflected the company’s commitment to advancing extravascular therapies designed to improve patient outcomes. The AtaCor-Abbott EV-ICD system remains investigational and has not received regulatory approval or commercial availability. Growing Interest in Implantable Cardiac Devices The development of alternative ICD technologies comes as demand for advanced cardiac rhythm management solutions continues to grow. Implantable cardioverter-defibrillators remain a critical therapy for preventing sudden cardiac death in patients at risk of dangerous ventricular arrhythmias. However, innovation in the field is increasingly focused on improving implantation techniques, reducing procedural complexity and developing technologies that minimise reliance on traditional transvenous approaches. Why the ALARION-EV Trial Matters Successful results from the ALARION-EV study could support the development of a new category of extravascular ICD technology. By evaluating whether an EV-ICD system can provide effective defibrillation therapy without traditional intracardiac leads, AtaCor aims to address ongoing challenges within cardiac rhythm management and expand treatment options for patients requiring implantable defibrillator therapy. Summary AtaCor Medical has enrolled the first patient in its ALARION-EV pivotal clinical trial evaluating an investigational extravascular implantable cardioverter-defibrillator (EV-ICD) system. The study will assess the safety and effectiveness of AtaCor’s parasternal EV-ICD technology, which combines the company’s Atala lead with Abbott’s pulse generator. If successful, the trial could support regulatory submission and advance the development of next-generation cardiac rhythm management solutions. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The agreement gives AstraZeneca exclusive rights to develop, manufacture and commercialise TQC3721 outside China, expanding the company’s respiratory pipeline with an investigational PDE3/4 inhibitor targeting chronic respiratory diseases including chronic obstructive pulmonary disease (COPD). AstraZeneca and Sino Biopharmaceutical subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) have entered into an exclusive licensing agreement for TQC3721, an inhaled phosphodiesterase 3/4 (PDE3/4) inhibitor currently in clinical development for respiratory diseases. Under the agreement, AstraZeneca will gain rights to develop, manufacture and commercialise TQC3721 outside China, while also securing exclusive global rights to certain future development programmes. Sino Biopharmaceutical will receive an upfront payment of $200 million from AstraZeneca, with additional development, regulatory and commercial milestones potentially increasing the total value of the collaboration to $1.9 billion. The deal also includes tiered royalties on annual net sales, which could reach double-digit percentages for TQC3721 products. AstraZeneca Expands Respiratory Pipeline With PDE3/4 Inhibitor TQC3721 is an inhaled PDE3/4 inhibitor designed to deliver both bronchodilator and anti-inflammatory effects by targeting two pathways involved in respiratory disease. Sino Biopharmaceutical is developing the therapy for chronic respiratory conditions, including chronic obstructive pulmonary disease (COPD), where persistent airway inflammation and reduced lung function remain significant treatment challenges. The company believes dual inhibition of PDE3 and PDE4 could provide complementary benefits by improving lung function, reducing exacerbations and addressing broader disease burden compared with therapies targeting individual pathways. The programme is being developed in two formulations: Nebulised TQC3721, currently being evaluated in a Phase III clinical trial in China. Dry powder inhaler formulation, currently being assessed in a Phase II study. Phase IIb COPD Data Support Further Development Early clinical data have strengthened interest in TQC3721 as a potential next-generation respiratory therapy. In a Phase IIb study evaluating the nebulised formulation in patients with COPD, Sino Biopharmaceutical reported that TQC3721 demonstrated a potential best-in-class profile. The positive findings supported progression into late-stage development, with the Phase III trial designed to further evaluate the therapy’s safety and efficacy in COPD patients. If successful, TQC3721 could provide an additional treatment option in a respiratory market where companies continue to seek therapies capable of improving symptom control, reducing exacerbations and supporting long-term disease management. Strategic Importance for AstraZeneca’s Respiratory Portfolio The collaboration reinforces AstraZeneca’s continued focus on respiratory medicine, an area where the company has established a strong global presence through therapies for asthma and COPD. By gaining access to TQC3721, AstraZeneca adds an investigational inhaled therapy with a differentiated mechanism of action to its pipeline. The agreement combines Sino Biopharmaceutical’s discovery capabilities and clinical development progress in China with AstraZeneca’s global expertise in respiratory medicine and commercialisation infrastructure. Sino Biopharmaceutical said the partnership will help accelerate the global development of TQC3721 and maximise its potential clinical and commercial value. Growing Momentum Behind China Pharma Partnerships The AstraZeneca-Sino Biopharmaceutical agreement reflects the growing role of Chinese biotechnology and pharmaceutical companies in global licensing activity. For Sino Biopharmaceutical, the deal represents its second major out-licensing transaction with a multinational pharmaceutical company in 2026. Earlier this year, the company entered into a separate collaboration with Sanofi involving the experimental oral JAK/ROCK inhibitor rovadicitinib. AstraZeneca has also continued to expand its presence in China through strategic partnerships, including collaborations focused on innovative drug discovery platforms and emerging therapeutic areas. Why the TQC3721 Deal Matters The agreement highlights continued investment in next-generation respiratory medicines as pharmaceutical companies look beyond established COPD treatments. For AstraZeneca, TQC3721 provides access to a late-stage respiratory asset with potential applications in a large and growing patient population. For Sino Biopharmaceutical, the partnership provides global development expertise and commercial reach needed to advance its respiratory innovation beyond China. A successful clinical programme could position TQC3721 as a potential differentiated treatment option for COPD and other chronic respiratory diseases. Summary AstraZeneca has signed an exclusive licensing agreement with Sino Biopharmaceutical subsidiary CTTQ for TQC3721, an inhaled PDE3/4 inhibitor being developed for chronic respiratory diseases including COPD. The deal includes a $200 million upfront payment and could generate up to $1.9 billion in milestone payments, alongside tiered royalties. Currently in Phase III development in China, TQC3721 represents AstraZeneca’s latest move to strengthen its respiratory pipeline through strategic partnerships and emerging global innovation. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The FDA has approved Sarclisa Escena, a subcutaneous on-body injector formulation of Sanofi’s multiple myeloma therapy isatuximab, becoming the first cancer treatment authorised in the US for delivery through an on-body injector system. Sanofi has secured US Food and Drug Administration (FDA) approval for Sarclisa Escena, a new subcutaneous (SC) formulation of its multiple myeloma therapy Sarclisa (isatuximab-irfc) delivered through an on-body injector (OBI). The approval represents a milestone in oncology drug delivery, as Sarclisa Escena becomes the first cancer therapy approved in the US that can be administered using an on-body injector alongside manual subcutaneous injection. Sarclisa Escena is approved across all existing US indications for the intravenous (IV) formulation of Sarclisa in multiple myeloma, providing healthcare professionals and patients with an additional treatment administration option. New Sarclisa Formulation Expands Multiple Myeloma Treatment Options Multiple myeloma is a blood cancer caused by the abnormal growth of plasma cells in the bone marrow, leading to complications including bone damage, anaemia, kidney problems and weakened immune function. Sarclisa is a monoclonal antibody targeting CD38, a protein expressed on multiple myeloma cells. By binding to CD38, the therapy helps activate immune mechanisms that attack and eliminate cancer cells. The newly approved Sarclisa Escena formulation allows the medicine to be delivered subcutaneously through either: The CirCLIQ on-body injector (OBI), providing automated hands-free administration. Manual subcutaneous injection, offering additional flexibility for healthcare providers. The approval covers Sarclisa’s existing US indications, including use in combination treatment regimens for patients with relapsed or refractory multiple myeloma and newly diagnosed disease. Phase III IRAKLIA Trial Supports FDA Approval The FDA approval was supported by clinical data from multiple studies, including the Phase III IRAKLIA non-inferiority trial. The study compared Sarclisa Escena delivered through the CirCLIQ on-body injector with the existing intravenous formulation in patients with multiple myeloma. In IRAKLIA, patients receiving Sarclisa Escena alongside pomalidomide and dexamethasone achieved an objective response rate (ORR) of 71.1%. This compared with an ORR of 70.5% among patients receiving the intravenous Sarclisa formulation with the same treatment combination. The trial demonstrated that the subcutaneous on-body injector formulation achieved comparable: Efficacy outcomes Pharmacokinetic exposure Overall safety profile compared with the established IV formulation. On-Body Injector Technology Reduces Treatment Burden The CirCLIQ on-body injector was developed using Enable Injections’ enFuse platform, a technology designed to simplify the administration of large-volume injectable medicines. The wearable device uses a retractable 30-gauge needle and is designed to automatically deliver the medicine without requiring healthcare professionals to manually administer prolonged injections. Sanofi said the system aims to reduce the physical effort associated with delivering high-resistance injections while allowing healthcare professionals to spend more time monitoring patients during treatment. The technology could help improve the treatment experience for patients receiving long-term cancer therapies by reducing administration complexity and shortening time spent in clinical settings. Sarclisa Escena Demonstrates Comparable Safety Profile Safety findings from the IRAKLIA trial were consistent with the known safety profile of intravenous Sarclisa. However, the subcutaneous on-body injector formulation demonstrated a reduction in systemic administration-related reactions. Systemic administration reactions occurred in: 1.5% of patients receiving Sarclisa Escena 25% of patients receiving intravenous Sarclisa The results suggest that the new delivery method may provide a more convenient administration approach without compromising the established clinical profile of the therapy. Impact on the Future of Oncology Drug Delivery The FDA approval of Sarclisa Escena reflects a wider shift towards improving convenience and reducing treatment burden in oncology. As more cancer therapies move beyond traditional intravenous infusion models, pharmaceutical companies are increasingly exploring alternative delivery technologies that can support outpatient treatment, improve patient experience and optimise healthcare resources. Sanofi’s approval of Sarclisa Escena positions the company at the forefront of this movement, introducing the first FDA-approved oncology treatment delivered through an on-body injector. Why This Approval Matters The approval of Sarclisa Escena provides patients with multiple myeloma and healthcare providers with a new way to administer an established therapy. By combining comparable efficacy and safety with a potentially simpler delivery method, the treatment could help reduce the burden associated with long-term cancer care. The decision also highlights the growing importance of drug delivery innovation alongside advances in oncology therapeutics, as companies seek to make complex treatments more accessible and patient-friendly. Summary Sanofi has received FDA approval for Sarclisa Escena, a subcutaneous on-body injector formulation of its multiple myeloma therapy isatuximab. Supported by Phase III IRAKLIA data, the therapy demonstrated comparable efficacy and safety to intravenous Sarclisa while significantly reducing administration-related reactions and treatment complexity. The approval marks the first FDA-approved oncology drug delivered through an on-body injector and represents a significant advance in the evolution of cancer treatment delivery. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Germany’s healthcare system overhaul introduces billions in savings measures while increasing pressure on pharmaceutical companies. German lawmakers have approved a major healthcare cost-reduction package aimed at addressing the country’s growing budget pressures, introducing measures that will significantly increase financial contributions from the pharmaceutical industry. The reforms, approved by Germany’s federal and state governments, are designed to reduce healthcare spending by €16.3 billion ($18.6 billion) as the country faces a projected budget shortfall of more than €40 billion ($45.8 billion) by 2030. While the measures are intended to improve the sustainability of Germany’s statutory health insurance system, they have faced strong opposition from pharmaceutical companies, with several major drugmakers warning that the changes could affect future investment in the country. Germany Healthcare Reform Targets Pharmaceutical Spending A central part of the legislation is a significant increase in mandatory pharmaceutical rebates paid by drug manufacturers. The reforms will: Increase the legally required pharmaceutical rebate from 7% to 15.5% Introduce an additional 9% rebate on patented vaccines Freeze vaccine prices until 2030 Limit hospital cost increases until 2029 Increase healthcare co-payments for some services According to the German Bundestag, the pharmaceutical rebate increase is intended to ensure that the industry makes a direct contribution towards controlling healthcare expenditure. The final legislation represents a compromise compared with earlier proposals that would have introduced a dynamic rebate system linked to overall pharmaceutical spending and healthcare system revenues. Drugmakers had criticised the original approach, arguing that variable rebates would make financial planning and investment decisions more difficult. Government Says Reform Is Necessary to Control Healthcare Costs German Health Minister Nina Warken said the reforms were necessary given the scale of the country’s financial challenge. “With necessary savings of almost €19 billion in the coming year alone, it is clear that there will be noticeable changes and that this law will demand something from everyone,” Warken said. The German government argues that the measures are required to protect the long-term sustainability of the statutory health insurance system, which provides coverage for the majority of the country’s population. However, pharmaceutical companies have warned that increased cost pressures could impact research investment, manufacturing expansion and the availability of innovative medicines. Pharmaceutical Industry Pushes Back Against German Healthcare Changes The reforms have received strong criticism from pharmaceutical leaders, who argue that Germany risks becoming a less attractive location for investment. Several major pharmaceutical companies raised concerns after the healthcare overhaul was initially proposed earlier in 2026. Pfizer Raises Investment Concerns Pfizer CEO Albert Bourla warned German Chancellor Friedrich Merz that the reforms could damage Germany’s attractiveness as a destination for pharmaceutical investment. Bourla also withdrew from an international investor conference in Germany following the announcement of the proposals. Roche Reviews Future Investment Plans Roche Pharma CEO Daniel Steiners also said the company would reassess future investment decisions in Germany due to concerns over the changing healthcare environment. Eli Lilly Reduces Manufacturing Investment Eli Lilly reduced its planned investment in a manufacturing facility in Rhineland-Palatinate. The company cut the planned spending on the site, which was intended to support production of its weight-loss medicines, from approximately €2.3 billion ($2.7 billion). Boehringer Ingelheim Scales Back Spending German pharmaceutical company Boehringer Ingelheim also reduced planned investment in its domestic operations, cancelling more than €900 million ($1 billion) in planned expenditure. US Government Reviews German Drug Pricing Policies The healthcare reforms have also attracted attention beyond Germany. The US government launched an investigation into Germany’s pharmaceutical pricing policies, examining whether what it described as persistent underpayment for innovative medicines could represent an unreasonable or discriminatory burden on US pharmaceutical companies. The review reflects broader international tensions around medicine pricing, with governments attempting to control healthcare costs while pharmaceutical companies argue that lower reimbursement can affect innovation and investment. What Germany’s Healthcare Reform Means for Pharma Germany remains one of the world’s largest pharmaceutical markets, but the latest reforms highlight the growing challenge facing healthcare systems globally: balancing affordability with continued investment in innovation. For pharmaceutical companies, the increased rebate requirements represent a direct reduction in potential revenue from the German market. The industry will now be closely monitoring whether the reforms influence: future research and development investment manufacturing expansion decisions clinical trial activity availability of newly launched medicines While Germany’s government views the changes as necessary cost controls, pharmaceutical companies argue that maintaining investment incentives will be critical to ensuring continued access to innovative therapies. Summary Germany has approved a major healthcare cost-saving package designed to reduce spending by €16.3 billion, including a significant increase in pharmaceutical rebates and new pricing restrictions. The reforms increase the pharmaceutical rebate rate from 7% to 15.5% and introduce additional measures targeting healthcare expenditure. While policymakers argue the changes are needed to strengthen the country’s healthcare system, major pharmaceutical companies including Pfizer, Roche, Eli Lilly and Boehringer Ingelheim have warned that the reforms could impact future investment decisions in Germany. The legislation highlights the ongoing global debate between healthcare affordability and maintaining incentives for pharmaceutical innovation. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

How much do cardiologists make in 2026? Cardiologists remain among the highest-compensated physician specialists in the United States, with new data from the AMGA 2026 Medical Group Compensation and Productivity Survey showing continued growth in cardiology compensation. For general non-invasive cardiologists, median compensation reached $648,852 in 2026, representing a 5.4% increase year-over-year. At the same time, cardiology productivity increased more modestly, with median work relative value units (wRVUs) rising 1.5% to 9,415. For cardiologists evaluating employment contracts, negotiating compensation packages or benchmarking career progression, understanding how salary growth compares with productivity expectations provides valuable insight into current market conditions. Key Findings: Cardiologist Compensation in 2026 According to the AMGA 2026 Medical Group Compensation and Productivity Survey: Median cardiologist compensation: $648,852 Year-over-year salary growth: +5.4% Median work RVUs: 9,415 Year-over-year wRVU growth: +1.5% Compensation per wRVU: $68.79 Compensation per wRVU growth: +2.9% The latest benchmarks suggest cardiology compensation growth is currently outpacing productivity growth, highlighting continued demand for cardiovascular specialists. Cardiologist Salary in 2026: Compensation Increased 5.4% The AMGA survey shows median compensation for general non-invasive cardiologists increased from: Year Median Compensation 2025 $615,621 2026 $648,852 This represents: +$33,231 increase year-over-year 5.4% compensation growth For practicing cardiologists, this provides a useful benchmark when assessing whether current compensation remains aligned with national market trends. For physicians negotiating new employment agreements, compensation benchmarks can help evaluate: base salary offers productivity incentives annual increases retention packages Cardiology Productivity Trends: Are wRVUs Increasing? Salary growth is only one part of physician compensation. Many cardiology contracts remain closely linked to productivity metrics, particularly work relative value units (wRVUs), which measure clinical activity and physician output. The AMGA data shows: Metric 2025 2026 Change Median wRVUs 9,274 9,415 +1.5% The increase indicates that cardiologists generated slightly higher clinical productivity in 2026. However, productivity growth was significantly lower than compensation growth, suggesting that higher earnings were not solely driven by increased workload. Potential factors influencing compensation growth include: continued demand for cardiovascular specialists physician recruitment challenges workforce shortages adjustments to physician compensation models Cardiology Compensation Per wRVU: What Does It Mean? The compensation-to-wRVU ratio shows how much physicians receive for each unit of productivity generated. For general non-invasive cardiology: Year Compensation per wRVU 2025 $66.80 2026 $68.79 This represents: 2.9% growth year-over-year A higher compensation-per-wRVU ratio may indicate that employers are increasing financial incentives to attract and retain cardiologists. For physicians, this metric can be particularly useful when reviewing productivity-based compensation plans. A contract may appear competitive based on total salary, but the underlying relationship between compensation and expected wRVUs determines whether the workload expectations are realistic. Why Cardiologists Should Pay Attention to Compensation Benchmarks Compensation data provides more than a salary comparison. For cardiologists, market benchmarks can support important career decisions. Contract Negotiations National compensation data can help physicians understand whether an offer is competitive. Key areas to evaluate include: guaranteed compensation wRVU thresholds bonus structures compensation per wRVU rates partnership opportunities Career Planning Cardiology remains one of the most financially attractive physician specialties. Benchmarking can help physicians compare opportunities across: hospital employment private practice academic medicine health system positions Understanding market rates can also support career decisions around location, subspecialisation and employment models. Productivity Expectations Compensation models increasingly connect physician earnings with measurable productivity. Tracking changes in: wRVUs compensation per wRVU salary growth can help cardiologists understand whether increased clinical expectations are being appropriately recognised . Cardiology Compensation Outlook: Demand Remains Strong Demand for cardiovascular specialists continues to grow as healthcare systems manage ageing populations and increasing rates of cardiovascular disease. At the same time, healthcare organisations face ongoing financial pressures, reimbursement challenges and physician workforce shortages. This creates a competitive environment for cardiology talent. The latest AMGA data suggests that employers are continuing to increase compensation to attract and retain cardiologists, even as productivity growth remains relatively modest. Summary: Cardiologist Salary Trends in 2026 The AMGA 2026 Medical Group Compensation and Productivity Survey shows continued growth in cardiologist compensation. General non-invasive cardiologists recorded: Median compensation of $648,852 5.4% year-over-year salary growth 9,415 median wRVUs $68.79 compensation per wRVU While productivity increased by 1.5%, compensation growth was stronger, suggesting that market demand and physician recruitment pressures are contributing factors in rising cardiology salaries. For cardiologists reviewing contracts, evaluating career opportunities or benchmarking their current compensation, AMGA data provides an important reference point for understanding the 2026 physician compensation landscape. Source AMGA 2026 Medical Group Compensation and Productivity Survey. Data reflects 2025 compensation reported by participating medical groups and health systems. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

How much are physicians earning in 2026? Physician compensation continued to rise in 2026, with new data from the AMGA 2026 Medical Group Compensation and Productivity Survey showing that healthcare providers experienced further growth in both compensation and productivity. The latest survey found that overall clinical compensation increased 4.3% year-over-year, while median work relative value units (wRVUs) increased by 2.4%. The data provides insight into how physician salaries are changing across major categories, including: primary care physicians medical specialists surgical specialists radiology, anesthesiology and pathology advanced practice clinicians (APCs) For physicians reviewing employment contracts, negotiating compensation packages or benchmarking career progression, understanding the relationship between salary growth and productivity expectations is becoming increasingly important. Key Findings: Physician Compensation Trends in 2026 According to the AMGA 2026 Medical Group Compensation and Productivity Survey: Overall physician compensation growth: +4.3% Overall wRVU growth: +2.4% Primary care compensation growth: +3.7% Medical specialty compensation growth: +4.3% Surgical specialty compensation growth: +3.2% Radiology/anesthesiology/pathology compensation growth: +5.7% APC compensation growth: +4.1% The survey reflects compensation and productivity data from 451 medical groups and health systems representing nearly 188,000 providers across more than 190 specialties. The overall picture suggests that physician compensation continues to increase, although the pace of growth varies significantly depending on specialty. Physician Salary Growth in 2026: Compensation Increased Across Every Major Category The AMGA data shows continued salary growth across all major physician groups. Specialty Category Compensation Growth 2026 Overall +4.3% Primary Care +3.7% Medical Specialties +4.3% Surgical Specialties +3.2% Radiology/Anesthesiology/Pathology +5.7% APCs +4.1% Among physician groups, radiology, anesthesiology and pathology recorded the strongest compensation growth at 5.7%, while surgical specialties saw the lowest increase at 3.2%. For physicians, this highlights that compensation trends are not moving uniformly across healthcare. Factors influencing salary growth may include: physician shortages specialty-specific demand recruitment pressures changing compensation models healthcare organisations competing for experienced providers Physician Productivity Trends: Are Doctors Working More for Higher Pay? Compensation growth does not tell the complete story. Many physician employment agreements link earnings to productivity metrics, particularly work relative value units (wRVUs). The AMGA survey shows: Category wRVU Growth 2026 Overall +2.4% Primary Care +2.0% Medical Specialties +2.0% Surgical Specialties +2.4% Radiology/Anesthesiology/Pathology +3.1% APCs +3.0% Overall physician productivity increased by 2.4%, slightly below compensation growth of 4.3%. This suggests that salary increases are not being driven purely by physicians generating higher clinical volume. Instead, compensation growth may also reflect: market competition for physicians efforts to improve retention adjustments to fair market value benchmarks increased demand for specialist care What Does Compensation Per wRVU Mean for Physicians? One of the most important metrics in physician compensation models is the relationship between pay and productivity. The compensation-per-wRVU ratio helps show how much physicians are being paid for each unit of clinical production. A higher ratio can indicate that physicians are receiving greater financial recognition for their productivity. For physicians reviewing employment agreements, this metric can help answer important questions: Is my productivity target realistic? Does my compensation reflect my workload? How does my contract compare with market benchmarks? Compensation structures vary significantly by specialty, which is why specialty-specific benchmarks are essential. For example, a cardiologist, gastroenterologist and orthopedic surgeon may all have different productivity expectations and compensation-per-wRVU levels. Why Physicians Should Pay Attention to Compensation Benchmarks Salary data is not just about comparing earnings. For physicians, compensation benchmarks can influence major career decisions. Contract Negotiations Market data can help physicians evaluate: base salary offers productivity incentives bonus structures wRVU thresholds annual compensation reviews Understanding national benchmarks provides a stronger position when negotiating employment agreements. Career Planning Physician compensation varies considerably depending on specialty. The AMGA data highlights why doctors should compare their own specialty rather than relying on overall physician averages. Career decisions around: specialty choice practice setting hospital employment private practice opportunities can all be influenced by compensation trends. Productivity Expectations Many modern physician contracts combine guaranteed compensation with productivity incentives. Understanding changes in: salary growth wRVUs compensation-per-wRVU helps physicians determine whether additional workload is being appropriately rewarded. Which Physician Specialties Saw the Biggest Salary Increases in 2026? The largest compensation increase among major physician categories came from: Radiology, Anesthesiology and Pathology +5.7% This was followed by: Medical Specialties +4.3% Primary Care +3.7% Surgical Specialties +3.2% Within individual specialties, compensation trends varied further. Examples include: General non-invasive cardiology: $648,852 (+5.4%) Gastroenterology: $656,500 (+3.6%) Hematology and medical oncology: $591,080 (+6.2%) Orthopedic surgery: $751,350 (+0.3%) These differences demonstrate why specialty-level compensation benchmarking is more valuable than looking only at overall physician averages. The Outlook for Physician Compensation in 2026 Physician compensation continues to be shaped by a complex healthcare environment. Medical groups and health systems are balancing: rising demand for healthcare services physician workforce shortages reimbursement pressures changing care delivery models increased use of advanced practice clinicians The latest AMGA data suggests that physicians continue to see compensation growth, but the relationship between pay, productivity and specialty demand remains highly individual. For doctors, understanding specialty-specific market benchmarks will become increasingly important when evaluating career opportunities. Summary: Physician Salary Trends in 2026 The AMGA 2026 Medical Group Compensation and Productivity Survey shows continued growth in physician compensation across the US healthcare system. Key findings include: Overall physician compensation increased 4.3% wRVUs increased 2.4% Medical specialties increased 4.3% Primary care increased 3.7% Surgical specialties increased 3.2% While physician salaries continue to rise, compensation growth varies significantly by specialty. For physicians evaluating contracts, planning career moves or benchmarking their current earnings, understanding salary trends and productivity expectations provides valuable insight into the changing healthcare employment market. Source AMGA 2026 Medical Group Compensation and Productivity Survey. Data reflects 2025 compensation reported by participating medical groups and health systems. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

How much are gastroenterologists earning in 2026? Gastroenterologists remain among the highest-compensated medical specialists in the United States, with the latest AMGA 2026 Medical Group Compensation and Productivity Survey showing continued growth in physician earnings alongside modest increases in clinical productivity. For gastroenterologists evaluating employment contracts, negotiating compensation packages or benchmarking their current position against national market data, understanding the relationship between salary growth, workload and productivity is essential. The latest AMGA data shows that median compensation for gastroenterologists reached $656,500 in 2026, representing a 3.6% increase year-over-year. At the same time, productivity growth was more limited, with median work relative value units (wRVUs) increasing by 0.5%, suggesting compensation growth has exceeded changes in measured clinical output. For physicians, this distinction matters. A rising salary does not necessarily mean a corresponding increase in workload — and compensation benchmarks can provide valuable leverage during contract discussions. How Much Do Gastroenterologists Earn in 2026? According to the AMGA 2026 Medical Group Compensation and Productivity Survey, median compensation for gastroenterologists increased from: Year Median Compensation 2025 $633,422 2026 $656,500 This represents an annual increase of: +$23,078 or: 3.6% growth year-over-year Gastroenterology continues to rank among the highest-paid medical specialties, reflecting the complexity of digestive disease management, demand for procedural expertise and the financial contribution generated through diagnostic and therapeutic procedures. For gastroenterologists reviewing employment agreements, this benchmark provides a reference point when assessing whether base salary, incentive structures and productivity expectations align with current market conditions. Gastroenterologist Productivity Trends: Are wRVUs Increasing? Compensation alone does not provide the complete picture. Many gastroenterology employment models are influenced by productivity measures, particularly work RVUs, which are designed to reflect physician workload and clinical activity. The AMGA survey shows: Metric 2025 2026 Change Median wRVUs 9,008 9,052 +0.5% The increase indicates that gastroenterologists generated slightly higher levels of measured productivity compared with the previous year. However, compensation growth was significantly higher than wRVU growth, meaning the market value of gastroenterology services increased faster than reported productivity levels. This may reflect several factors, including: Continued demand for digestive disease specialists Pressure to recruit and retain gastroenterologists The value of procedural expertise within health systems Competition for experienced physicians in high-demand specialties What Does Compensation Per wRVU Mean for Gastroenterologists? The compensation-to-wRVU ratio provides another important benchmark by showing how much compensation physicians receive for each unit of productivity. For gastroenterology: Year Compensation per wRVU 2025 $70.47 2026 $72.28 This represents: 2.6% increase year-over-year A rising compensation per wRVU ratio suggests gastroenterologists are receiving greater financial recognition relative to productivity output. For physicians negotiating contracts, this figure can be particularly important when reviewing: Productivity incentive formulas Bonus thresholds Conversion rates Fair market value assessments A contract offering a lower compensation-per-wRVU rate may place greater pressure on physicians to generate higher volumes to achieve comparable earnings. Why Gastroenterologists Should Pay Attention to Compensation Trends Contract negotiations National compensation benchmarks provide gastroenterologists with evidence when reviewing employment offers, renewals or productivity-based compensation models. Key questions include: Is the guaranteed salary competitive? Are productivity targets achievable? Is the wRVU conversion rate aligned with market benchmarks? Are incentives rewarding additional clinical activity? Career planning Compensation data can help gastroenterologists evaluate career opportunities across different practice models, including: Hospital-employed positions Private practice groups Academic medicine Partnership opportunities Understanding market trends can help physicians assess whether a proposed role reflects current specialty demand. Understanding productivity expectations Gastroenterology is a specialty where compensation is often closely linked to procedural volume. Monitoring changes in: Compensation wRVUs Compensation per wRVU helps physicians understand whether income growth is being driven by: Increased workload Higher market demand Improved reimbursement structures Changes in compensation methodology The Bigger Picture for Gastroenterology Demand for gastroenterology services continues to increase as healthcare systems manage growing rates of digestive diseases, colorectal cancer screening requirements and chronic gastrointestinal conditions. At the same time, medical groups face pressure from reimbursement changes, workforce shortages and rising operational costs. For gastroenterologists, compensation data provides insight into how healthcare organisations are responding to these competing pressures. The latest AMGA figures suggest the specialty remains highly valued, with compensation increasing faster than productivity growth. Summary The AMGA 2026 Medical Group Compensation and Productivity Survey shows that gastroenterologists remain among the highest-compensated physician specialists in the United States. Key findings include: Median gastroenterologist compensation reached $656,500 in 2026 Compensation increased 3.6% year-over-year Median wRVUs increased 0.5% to 9,052 Compensation per wRVU increased 2.6% to $72.28 For gastroenterologists assessing employment contracts, negotiating compensation packages or benchmarking their careers, these figures provide a data-driven view of where the specialty stands in the current physician market. Source AMGA 2026 Medical Group Compensation and Productivity Survey. Data reflects 2025 compensation reported by participating medical groups and health systems. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com